Cargando…

Understanding the Patient PPI Journey: Results of a Survey on PPI Treatment Initiation and Patient Experience

INTRODUCTION: Proton pump inhibitors (PPIs) used in the management of gastro-esophageal reflux disease (GORD) are among the most frequently prescribed classes of drug worldwide. Currently, however, physicians are prescribing PPIs for extended periods, often without an indication, which is not in lin...

Descripción completa

Detalles Bibliográficos
Autores principales: Plehhova, Kate, Paquette, Natalie, Gould, James, Coyle, Cathal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8961351/
https://www.ncbi.nlm.nih.gov/pubmed/35323078
http://dx.doi.org/10.1177/21501319221088688
_version_ 1784677579481939968
author Plehhova, Kate
Paquette, Natalie
Gould, James
Coyle, Cathal
author_facet Plehhova, Kate
Paquette, Natalie
Gould, James
Coyle, Cathal
author_sort Plehhova, Kate
collection PubMed
description INTRODUCTION: Proton pump inhibitors (PPIs) used in the management of gastro-esophageal reflux disease (GORD) are among the most frequently prescribed classes of drug worldwide. Currently, however, physicians are prescribing PPIs for extended periods, often without an indication, which is not in line with current guidance and therefore preventing appropriate reflux management. Inappropriate or excessive PPI prescribing is becoming increasingly visible, yet there is currently little research available on the impact such current practice has on the patient experience. This study aims to understand patient attitudes toward their PPI treatment and the impact current PPI prescribing patterns have on the patient experience. METHODS: An online survey of current and previous users of PPI for GORD was conducted in the UK and Germany. Topics covered included prior steps taken before first consultation with a physician, initial recommendations, PPI treatment initiation and duration, use of PPI, management of reflux whilst taking a PPI, stopping PPI treatment, and patient attitudes. RESULTS: Among 566 patient participants (UK, n = 372; Germany, n = 194) 69% to 79% reported being prescribed medication at their first visit to a physician, of which 61% to 68% were prescribed a PPI either alone or combined with another treatment. 41% to 48% of patients answered “don’t know” when asked how long they expected to continue taking their PPI. 49% to 50% of patients currently on PPIs also reported having concerns with regards to long-term treatment. 70% of patients recalled being well informed on dosage and treatment regimens. However, other safety and usage information was reported as being less frequently discussed. CONCLUSIONS: Although patients reported concerns regarding ongoing long-term PPI treatment, this was not reflected in the prescribing pattern from physicians. More can be done to ensure patients are fully informed about their PPI treatment at consultation. Findings also suggest a disconnect exists between standard treatment guidelines and prescribing patterns, as experienced by patients.
format Online
Article
Text
id pubmed-8961351
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-89613512022-03-30 Understanding the Patient PPI Journey: Results of a Survey on PPI Treatment Initiation and Patient Experience Plehhova, Kate Paquette, Natalie Gould, James Coyle, Cathal J Prim Care Community Health Original Research INTRODUCTION: Proton pump inhibitors (PPIs) used in the management of gastro-esophageal reflux disease (GORD) are among the most frequently prescribed classes of drug worldwide. Currently, however, physicians are prescribing PPIs for extended periods, often without an indication, which is not in line with current guidance and therefore preventing appropriate reflux management. Inappropriate or excessive PPI prescribing is becoming increasingly visible, yet there is currently little research available on the impact such current practice has on the patient experience. This study aims to understand patient attitudes toward their PPI treatment and the impact current PPI prescribing patterns have on the patient experience. METHODS: An online survey of current and previous users of PPI for GORD was conducted in the UK and Germany. Topics covered included prior steps taken before first consultation with a physician, initial recommendations, PPI treatment initiation and duration, use of PPI, management of reflux whilst taking a PPI, stopping PPI treatment, and patient attitudes. RESULTS: Among 566 patient participants (UK, n = 372; Germany, n = 194) 69% to 79% reported being prescribed medication at their first visit to a physician, of which 61% to 68% were prescribed a PPI either alone or combined with another treatment. 41% to 48% of patients answered “don’t know” when asked how long they expected to continue taking their PPI. 49% to 50% of patients currently on PPIs also reported having concerns with regards to long-term treatment. 70% of patients recalled being well informed on dosage and treatment regimens. However, other safety and usage information was reported as being less frequently discussed. CONCLUSIONS: Although patients reported concerns regarding ongoing long-term PPI treatment, this was not reflected in the prescribing pattern from physicians. More can be done to ensure patients are fully informed about their PPI treatment at consultation. Findings also suggest a disconnect exists between standard treatment guidelines and prescribing patterns, as experienced by patients. SAGE Publications 2022-03-24 /pmc/articles/PMC8961351/ /pubmed/35323078 http://dx.doi.org/10.1177/21501319221088688 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Plehhova, Kate
Paquette, Natalie
Gould, James
Coyle, Cathal
Understanding the Patient PPI Journey: Results of a Survey on PPI Treatment Initiation and Patient Experience
title Understanding the Patient PPI Journey: Results of a Survey on PPI Treatment Initiation and Patient Experience
title_full Understanding the Patient PPI Journey: Results of a Survey on PPI Treatment Initiation and Patient Experience
title_fullStr Understanding the Patient PPI Journey: Results of a Survey on PPI Treatment Initiation and Patient Experience
title_full_unstemmed Understanding the Patient PPI Journey: Results of a Survey on PPI Treatment Initiation and Patient Experience
title_short Understanding the Patient PPI Journey: Results of a Survey on PPI Treatment Initiation and Patient Experience
title_sort understanding the patient ppi journey: results of a survey on ppi treatment initiation and patient experience
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8961351/
https://www.ncbi.nlm.nih.gov/pubmed/35323078
http://dx.doi.org/10.1177/21501319221088688
work_keys_str_mv AT plehhovakate understandingthepatientppijourneyresultsofasurveyonppitreatmentinitiationandpatientexperience
AT paquettenatalie understandingthepatientppijourneyresultsofasurveyonppitreatmentinitiationandpatientexperience
AT gouldjames understandingthepatientppijourneyresultsofasurveyonppitreatmentinitiationandpatientexperience
AT coylecathal understandingthepatientppijourneyresultsofasurveyonppitreatmentinitiationandpatientexperience